AlloVir (ALVR) Set to Announce Quarterly Earnings on Tuesday

AlloVir (NASDAQ:ALVRGet Free Report) is set to post its quarterly earnings results on Tuesday, February 13th.

AlloVir Stock Performance

ALVR opened at $0.72 on Monday. The firm has a market cap of $82.19 million, a P/E ratio of -0.43 and a beta of 0.84. AlloVir has a 52-week low of $0.62 and a 52-week high of $7.24. The business’s fifty day moving average is $1.13 and its 200-day moving average is $1.86.

Insider Activity at AlloVir

In other AlloVir news, CEO Diana Brainard sold 41,421 shares of the company’s stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $0.67, for a total value of $27,752.07. Following the transaction, the chief executive officer now directly owns 822,321 shares in the company, valued at approximately $550,955.07. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last three months, insiders have sold 113,794 shares of company stock worth $85,970. 39.97% of the stock is owned by company insiders.

Hedge Funds Weigh In On AlloVir

A number of institutional investors have recently added to or reduced their stakes in the business. Ensign Peak Advisors Inc boosted its holdings in shares of AlloVir by 27.0% in the 3rd quarter. Ensign Peak Advisors Inc now owns 7,300 shares of the company’s stock worth $58,000 after purchasing an additional 1,550 shares in the last quarter. Alliancebernstein L.P. lifted its holdings in AlloVir by 6.3% in the 3rd quarter. Alliancebernstein L.P. now owns 28,500 shares of the company’s stock worth $225,000 after buying an additional 1,700 shares during the period. PDT Partners LLC lifted its holdings in AlloVir by 10.3% in the 2nd quarter. PDT Partners LLC now owns 33,315 shares of the company’s stock worth $130,000 after buying an additional 3,117 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in AlloVir by 1.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 303,469 shares of the company’s stock worth $1,557,000 after buying an additional 4,409 shares during the period. Finally, MetLife Investment Management LLC lifted its holdings in AlloVir by 27.6% in the 2nd quarter. MetLife Investment Management LLC now owns 21,323 shares of the company’s stock worth $72,000 after buying an additional 4,613 shares during the period. 47.41% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

ALVR has been the topic of several analyst reports. Bank of America lowered AlloVir from a “buy” rating to an “underperform” rating in a report on Tuesday, December 26th. JPMorgan Chase & Co. lowered AlloVir from an “overweight” rating to an “underweight” rating in a research note on Friday, December 22nd. Piper Sandler lowered AlloVir from an “overweight” rating to a “neutral” rating in a research note on Friday, December 22nd. SVB Leerink lowered AlloVir from an “outperform” rating to a “market perform” rating in a research note on Friday, December 22nd. Finally, Leerink Partnrs lowered AlloVir from an “outperform” rating to a “market perform” rating in a research note on Friday, December 22nd. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat.com, AlloVir has a consensus rating of “Hold” and an average target price of $18.67.

Read Our Latest Research Report on ALVR

AlloVir Company Profile

(Get Free Report)

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.

Further Reading

Earnings History for AlloVir (NASDAQ:ALVR)

Receive News & Ratings for AlloVir Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AlloVir and related companies with MarketBeat.com's FREE daily email newsletter.